Furthermore, SLAMF6 expression was not restricted to a specific genetic subtype but expressed in all major subtypes, including the poor prognostic groups with myelodysplasia-related mutations (AML-MR) and TP53 mutations (Fig. 2c–f). This evidence concerns the gene TP53 and Myelodysplasia.